Cargando…

High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts

INTRODUCTION: In addition to its direct proinflammatory activity, extracellular high mobility group box protein 1 (HMGB1) can strongly enhance the cytokine response evoked by other proinflammatory molecules, such as lipopolysaccharide (LPS), CpG-DNA and IL-1β, through the formation of complexes. Ext...

Descripción completa

Detalles Bibliográficos
Autores principales: Wähämaa, Heidi, Schierbeck, Hanna, Hreggvidsdottir, Hulda S, Palmblad, Karin, Aveberger, Anne-Charlotte, Andersson, Ulf, Harris, Helena Erlandsson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239379/
https://www.ncbi.nlm.nih.gov/pubmed/21871094
http://dx.doi.org/10.1186/ar3450
_version_ 1782219179951128576
author Wähämaa, Heidi
Schierbeck, Hanna
Hreggvidsdottir, Hulda S
Palmblad, Karin
Aveberger, Anne-Charlotte
Andersson, Ulf
Harris, Helena Erlandsson
author_facet Wähämaa, Heidi
Schierbeck, Hanna
Hreggvidsdottir, Hulda S
Palmblad, Karin
Aveberger, Anne-Charlotte
Andersson, Ulf
Harris, Helena Erlandsson
author_sort Wähämaa, Heidi
collection PubMed
description INTRODUCTION: In addition to its direct proinflammatory activity, extracellular high mobility group box protein 1 (HMGB1) can strongly enhance the cytokine response evoked by other proinflammatory molecules, such as lipopolysaccharide (LPS), CpG-DNA and IL-1β, through the formation of complexes. Extracellular HMGB1 is abundant in arthritic joint tissue where it is suggested to promote inflammation as intra-articular injections of HMGB1 induce synovitis in mice and HMGB1 neutralizing therapy suppresses development of experimental arthritis. The aim of this study was to determine whether HMGB1 in complex with LPS, interleukin (IL)-1α or IL-1β has enhancing effects on the production of proinflammatory mediators by rheumatoid arthritis synovial fibroblasts (RASF) and osteoarthritis synovial fibroblasts (OASF). Furthermore, we examined the toll-like receptor (TLR) 4 and IL-1RI requirement for the cytokine-enhancing effects of the investigated HMGB1-ligand complexes. METHODS: Synovial fibroblasts obtained from rheumatoid arthritis (RA) and osteoarthritis (OA) patients were stimulated with HMGB1 alone or in complex with LPS, IL-1α or IL-1β. Tumour necrosis factor (TNF) production was determined by enzyme-linked immunospot assay (ELISPOT) assessment. Levels of IL-10, IL-1-β, IL-6 and IL-8 were measured using Cytokine Bead Array and matrix metalloproteinase (MMP) 3 production was determined by ELISA. RESULTS: Stimulation with HMGB1 in complex with LPS, IL-1α or IL-1β enhanced production of TNF, IL-6 and IL-8. HMGB1 in complex with IL-1β increased MMP production from both RASF and OASF. The cytokine production was inhibited by specific receptor blockade using detoxified LPS or IL-1 receptor antagonist, indicating that the synergistic effects were mediated through the partner ligand-reciprocal receptors TLR4 and IL-1RI, respectively. CONCLUSIONS: HMGB1 in complex with LPS, IL-1α or IL-1β boosted proinflammatory cytokine- and MMP production in synovial fibroblasts from RA and OA patients. A mechanism for the pathogenic role of HMGB1 in arthritis could thus be through enhancement of inflammatory and destructive mechanisms induced by other proinflammatory mediators present in the arthritic joint.
format Online
Article
Text
id pubmed-3239379
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32393792011-12-16 High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts Wähämaa, Heidi Schierbeck, Hanna Hreggvidsdottir, Hulda S Palmblad, Karin Aveberger, Anne-Charlotte Andersson, Ulf Harris, Helena Erlandsson Arthritis Res Ther Research Article INTRODUCTION: In addition to its direct proinflammatory activity, extracellular high mobility group box protein 1 (HMGB1) can strongly enhance the cytokine response evoked by other proinflammatory molecules, such as lipopolysaccharide (LPS), CpG-DNA and IL-1β, through the formation of complexes. Extracellular HMGB1 is abundant in arthritic joint tissue where it is suggested to promote inflammation as intra-articular injections of HMGB1 induce synovitis in mice and HMGB1 neutralizing therapy suppresses development of experimental arthritis. The aim of this study was to determine whether HMGB1 in complex with LPS, interleukin (IL)-1α or IL-1β has enhancing effects on the production of proinflammatory mediators by rheumatoid arthritis synovial fibroblasts (RASF) and osteoarthritis synovial fibroblasts (OASF). Furthermore, we examined the toll-like receptor (TLR) 4 and IL-1RI requirement for the cytokine-enhancing effects of the investigated HMGB1-ligand complexes. METHODS: Synovial fibroblasts obtained from rheumatoid arthritis (RA) and osteoarthritis (OA) patients were stimulated with HMGB1 alone or in complex with LPS, IL-1α or IL-1β. Tumour necrosis factor (TNF) production was determined by enzyme-linked immunospot assay (ELISPOT) assessment. Levels of IL-10, IL-1-β, IL-6 and IL-8 were measured using Cytokine Bead Array and matrix metalloproteinase (MMP) 3 production was determined by ELISA. RESULTS: Stimulation with HMGB1 in complex with LPS, IL-1α or IL-1β enhanced production of TNF, IL-6 and IL-8. HMGB1 in complex with IL-1β increased MMP production from both RASF and OASF. The cytokine production was inhibited by specific receptor blockade using detoxified LPS or IL-1 receptor antagonist, indicating that the synergistic effects were mediated through the partner ligand-reciprocal receptors TLR4 and IL-1RI, respectively. CONCLUSIONS: HMGB1 in complex with LPS, IL-1α or IL-1β boosted proinflammatory cytokine- and MMP production in synovial fibroblasts from RA and OA patients. A mechanism for the pathogenic role of HMGB1 in arthritis could thus be through enhancement of inflammatory and destructive mechanisms induced by other proinflammatory mediators present in the arthritic joint. BioMed Central 2011 2011-08-26 /pmc/articles/PMC3239379/ /pubmed/21871094 http://dx.doi.org/10.1186/ar3450 Text en Copyright ©2011 Wähämaa et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wähämaa, Heidi
Schierbeck, Hanna
Hreggvidsdottir, Hulda S
Palmblad, Karin
Aveberger, Anne-Charlotte
Andersson, Ulf
Harris, Helena Erlandsson
High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
title High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
title_full High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
title_fullStr High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
title_full_unstemmed High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
title_short High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
title_sort high mobility group box protein 1 in complex with lipopolysaccharide or il-1 promotes an increased inflammatory phenotype in synovial fibroblasts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239379/
https://www.ncbi.nlm.nih.gov/pubmed/21871094
http://dx.doi.org/10.1186/ar3450
work_keys_str_mv AT wahamaaheidi highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts
AT schierbeckhanna highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts
AT hreggvidsdottirhuldas highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts
AT palmbladkarin highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts
AT avebergerannecharlotte highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts
AT anderssonulf highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts
AT harrishelenaerlandsson highmobilitygroupboxprotein1incomplexwithlipopolysaccharideoril1promotesanincreasedinflammatoryphenotypeinsynovialfibroblasts